(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of -17.43% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 2.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.75%.
Maxcyte's revenue in 2024 is $45,599,600.On average, 2 Wall Street analysts forecast MXCT's revenue for 2024 to be $3,971,418,309, with the lowest MXCT revenue forecast at $3,966,144,181, and the highest MXCT revenue forecast at $3,976,692,437.
In 2025, MXCT is forecast to generate $4,862,745,924 in revenue, with the lowest revenue forecast at $4,725,618,598 and the highest revenue forecast at $4,999,873,249.